ZyGem buys MicoLab
This article was originally published in The Gray Sheet
Executive Summary
New Zealand-based ZyGem announces May 24 it has acquired microfluidic device maker MicroLab Diagnostics for an undisclosed amount. The company plans to integrate its DNA extraction and reagents and detection assays with MicroLab's microfluidic chip technology for "a broad range of applications." ZyGem expects to begin field testing of the combined system this year, "with commercial introduction planned for 2011," according to CEO Paul Kinnon. "We will initially target the forensic and government sectors, where we have already demonstrated convincing proof-of-concept, and which represent markets we estimate to exceed $3 billion annually in the U.S. alone," he added. As part of the agreement, ZyGem's senior management will relocate to MicroLab's Charlottesville, Va., headquarters, but the firm will retain its New Zealand labs
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.